Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Mucor Appendicitis Resolution Following Surgical Excision without Antifungal Therapy.

Naor S, Sher O, Grisaru-Soen G, Levin D, Elhasid R, Geffen Y, Hershkovitz D, Aizic A.

Isr Med Assoc J. 2018 Sep;20(9):592-593. No abstract available.

2.

Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA.

Fahoum I, Forer R, Volodarsky D, Vulih I, Bick T, Sarji S, Bamberger Z, Ben-Izhak O, Sabo E, Hershberg R, Hershkovitz D.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818793653. doi: 10.1177/1533033818793653.

3.

68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study.

Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, Zohar Y, Shibolet O, Even-Sapir E.

J Nucl Med. 2018 Jul 12. pii: jnumed.118.214833. doi: 10.2967/jnumed.118.214833. [Epub ahead of print]

PMID:
30002112
4.

PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.

Ghannam-Shahbari D, Jacob E, Kakun RR, Wasserman T, Korsensky L, Sternfeld O, Kagan J, Bublik DR, Aviel-Ronen S, Levanon K, Sabo E, Larisch S, Oren M, Hershkovitz D, Perets R.

Oncogene. 2018 Apr;37(17):2213-2224. doi: 10.1038/s41388-017-0040-z. Epub 2018 Jan 30.

PMID:
29379162
5.

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D.

Oncologist. 2018 May;23(5):566-572. doi: 10.1634/theoncologist.2017-0467. Epub 2018 Jan 25.

PMID:
29371474
6.

Proteolytic Nanoparticles Replace a Surgical Blade by Controllably Remodeling the Oral Connective Tissue.

Zinger A, Adir O, Alper M, Simon A, Poley M, Tzror C, Yaari Z, Krayem M, Kasten S, Nawy G, Herman A, Nir Y, Akrish S, Klein T, Shainsky-Roitman J, Hershkovitz D, Schroeder A.

ACS Nano. 2018 Feb 27;12(2):1482-1490. doi: 10.1021/acsnano.7b07983. Epub 2018 Jan 30.

PMID:
29365250
7.

Synthetic Cells Synthesize Therapeutic Proteins inside Tumors.

Krinsky N, Kaduri M, Zinger A, Shainsky-Roitman J, Goldfeder M, Benhar I, Hershkovitz D, Schroeder A.

Adv Healthc Mater. 2018 May;7(9):e1701163. doi: 10.1002/adhm.201701163. Epub 2017 Dec 28.

PMID:
29283226
8.

Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.

Blumenthal DT, Kanner AA, Aizenstein O, Cagnano E, Greenberg A, Hershkovitz D, Ram Z, Bokstein F.

World Neurosurg. 2018 Feb;110:e727-e737. doi: 10.1016/j.wneu.2017.11.105. Epub 2017 Nov 26.

PMID:
29183864
9.

Nanoparticles target early-stage breast cancer metastasis in vivo.

Goldman E, Zinger A, da Silva D, Yaari Z, Kajal A, Vardi-Oknin D, Goldfeder M, Schroeder JE, Shainsky-Roitman J, Hershkovitz D, Schroeder A.

Nanotechnology. 2017 Oct 27;28(43):43LT01. doi: 10.1088/1361-6528/aa8a3d. Epub 2017 Sep 5.

PMID:
28872058
10.

Correction: Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT.

Keller B, Zaidman I, Yousefi OS, Hershkovitz D, Stein J, Unger S, Schachtrup K, Sigvardsson M, Kuperman AA, Shaag A, Schamel WW, Elpeleg O, Warnatz K, Stepensky P.

J Exp Med. 2017 Jul 3;214(7):2165. doi: 10.1084/jem.2015111005242017c. Epub 2017 Jun 1. No abstract available.

11.

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.

Simon E, Bick T, Sarji S, Shentzer T, Prinz E, Yehiam L, Sabo E, Ben-Izhak O, Hershkovitz D.

Oncotarget. 2017 Jul 11;8(28):45736-45749. doi: 10.18632/oncotarget.17399.

12.

Molecular and Morphometric Tools for Next-Generation Pathology Diagnosis of Colon Carcinoma.

Fisher Y, Hershkovitz D.

Isr Med Assoc J. 2016 Jul;18(7):426-432. Review. No abstract available.

13.

Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.

Rachman-Tzemah C, Zaffryar-Eilot S, Grossman M, Ribero D, Timaner M, Mäki JM, Myllyharju J, Bertolini F, Hershkovitz D, Sagi I, Hasson P, Shaked Y.

Cell Rep. 2017 Apr 25;19(4):774-784. doi: 10.1016/j.celrep.2017.04.005.

14.

Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.

Asor E, Stav MY, Simon E, Fahoum I, Sabo E, Ben-Izhak O, Hershkovitz D.

PLoS One. 2017 Mar 13;12(3):e0173760. doi: 10.1371/journal.pone.0173760. eCollection 2017.

15.

The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.

Davidi S, Fremder E, Kan T, Raviv Z, Timaner M, Karin N, Hershkovitz D, Arohneim A, Shaked Y.

Oncotarget. 2017 Mar 7;8(10):16430-16444. doi: 10.18632/oncotarget.14857.

16.

Hairy cell leukemia-variant without typical morphology and with near-tetraploid DNA content.

Azoulay D, Sonkin V, Akria L, Rozano Gorelick A, Trakhtenbrot L, Hershkovitz D, Shaoul E, Rozen S, Dementiev E, Cohen HI, Suriu C, Braester A.

Cytometry B Clin Cytom. 2018 Jan;94(1):169-171. doi: 10.1002/cyto.b.21503. Epub 2017 Feb 6. No abstract available.

PMID:
27997757
17.

Theranostic barcoded nanoparticles for personalized cancer medicine.

Yaari Z, da Silva D, Zinger A, Goldman E, Kajal A, Tshuva R, Barak E, Dahan N, Hershkovitz D, Goldfeder M, Roitman JS, Schroeder A.

Nat Commun. 2016 Nov 10;7:13325. doi: 10.1038/ncomms13325.

18.

Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3.

Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, Merquiol E, Ben-Nun Y, Miller V, Rachman-Tzemah C, Timaner M, Mumblat Y, Ilan N, Loven D, Hershkovitz D, Satchi-Fainaro R, Blum G, P Sleeman J, Vlodavsky I, Shaked Y.

Cell Rep. 2016 Oct 25;17(5):1344-1356. doi: 10.1016/j.celrep.2016.09.083.

19.

Loss of Glycine Transporter 1 Causes a Subtype of Glycine Encephalopathy with Arthrogryposis and Mildly Elevated Cerebrospinal Fluid Glycine.

Kurolap A, Armbruster A, Hershkovitz T, Hauf K, Mory A, Paperna T, Hannappel E, Tal G, Nijem Y, Sella E, Mahajnah M, Ilivitzki A, Hershkovitz D, Ekhilevitch N, Mandel H, Eulenburg V, Baris HN.

Am J Hum Genet. 2016 Nov 3;99(5):1172-1180. doi: 10.1016/j.ajhg.2016.09.004. Epub 2016 Oct 20.

20.

Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT.

Keller B, Zaidman I, Yousefi OS, Hershkovitz D, Stein J, Unger S, Schachtrup K, Sigvardsson M, Kuperman AA, Shaag A, Schamel WW, Elpeleg O, Warnatz K, Stepensky P.

J Exp Med. 2016 Jun 27;213(7):1185-99. doi: 10.1084/jem.20151110. Epub 2016 May 30. Erratum in: J Exp Med. 2017 Jun 1;:.

Supplemental Content

Loading ...
Support Center